[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 189,347
  • Shares Outstanding, K 277,798
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -40,830 K
  • EBIT $ -111 M
  • EBITDA $ -104 M
  • 60-Month Beta 2.53
  • Price/Sales 95.58
  • Price/Cash Flow N/A
  • Price/Book 6.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.52
  • Most Recent Earnings $-0.16 on 08/12/26
  • Next Earnings Date 11/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 250.11% (+32.38%)
  • Historical Volatility 113.67%
  • IV Percentile 91%
  • IV Rank 43.26%
  • IV High 460.98% on 06/03/26
  • IV Low 89.34% on 09/11/25
  • Expected Move (DTE 22) 0.2380 (33.93%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 470
  • Volume Avg (30-Day) 767
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 100,896
  • Open Int (30-Day) 99,916
  • Expected Range 0.4635 to 0.9395

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.09
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.10
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5261 +32.54%
on 08/14/26
0.7500 -7.03%
on 08/19/26
+0.0232 (+3.44%)
since 07/27/26
3-Month
0.5261 +32.54%
on 08/14/26
1.5250 -54.28%
on 06/04/26
-0.4527 (-39.37%)
since 05/27/26
52-Week
0.5261 +32.54%
on 08/14/26
2.5500 -72.65%
on 10/06/25
-0.8327 (-54.42%)
since 08/27/25

Most Recent Stories

More News
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from...

HUMA : 0.6959 (+2.10%)
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –

HUMA : 0.6959 (+2.10%)
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK and NEW ORLEANS , Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces...

HUMA : 0.6959 (+2.10%)
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation...

HUMA : 0.6959 (+2.10%)
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel – –...

HUMA : 0.6959 (+2.10%)
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved...

HUMA : 0.6959 (+2.10%)
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with...

HUMA : 0.6959 (+2.10%)
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with...

HUMA : 0.6959 (+2.10%)
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF continues its investigation into ...

HUMA : 0.6959 (+2.10%)
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 0.6959 (+2.10%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 0.7476
2nd Resistance Point 0.7297
1st Resistance Point 0.7057
Last Price 0.6959
1st Support Level 0.6638
2nd Support Level 0.6459
3rd Support Level 0.6219

See More

52-Week High 2.5500
Fibonacci 61.8% 1.7769
Fibonacci 50% 1.5380
Fibonacci 38.2% 1.2992
Last Price 0.6959
52-Week Low 0.5261

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.